top of page
搜尋

Novotech agrees acquisition of Agilex Biolabs to expand bioanalytical capabilities in Australia

作家相片: nuaxia
nuaxia
32分钟前
讀畢需時 1 分鐘

Novotech has agreed to acquire Agilex Biolabs, adding specialist bioanalytical laboratory capabilities to its Australian clinical-development platform.


Agilex provides bioanalytical services supporting early-stage drug development and will broaden Novotech's ability to offer integrated laboratory and clinical services.


The acquisition strengthens Novotech's early-phase infrastructure in Australia and expands the range of services available to biotechnology and pharmaceutical sponsors.

Field

Content

Article Type

Deals

Companies

Novotech; Agilex Biolabs

Deal Type

Acquisition

Acquired Company

Agilex Biolabs

Sector

Contract research organisation and bioanalytical services

Capabilities

Bioanalysis; early-phase drug development support; laboratory services

Geography

Australia

What Happened

Novotech agreed to acquire Adelaide-based Agilex Biolabs.

Why It Matters

The transaction adds specialist bioanalytical laboratory capabilities to Novotech's existing clinical-development infrastructure.

Supporting Context

Agilex supports pharmaceutical and biotechnology clients with bioanalytical services used during early drug development.

Strategic Rationale

The acquisition enables Novotech to provide a more integrated clinical and laboratory offering to sponsors.

Potential Impact

Clients may be able to consolidate more early-phase clinical and bioanalytical work within a single service provider.

Key Takeaway

Novotech is expanding its Australian early-development platform through the acquisition of Agilex Biolabs.

What to Watch

Transaction completion, integration of Agilex capabilities and expansion of combined laboratory services.

Primary Source

Novotech

Relevant Date

25 September 2026


Discover how nuaxia can support your next medical education initiative:

 
 
 

留言

評等為 0(最高為 5 顆星)。
暫無評等

新增評等
bottom of page